This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes

This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes

Sulphonylureas (SU) have received a terrible press in recent years. A series of publications over many years have told us that SUs increase the risk of adverse cardiovascular outcomes in diabetes patients (usually relative to metformin in observational studies),1 analyses from ACCORD and other mega...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Ryder, R, Holman, R, Gwilt, M
Formaat:	Conference item
Gepubliceerd in:	Association of British Clinical Diabetologists 2016

Gelijkaardige items

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.
door: Holman, R, et al.
Gepubliceerd in: (1987)

Sulphonylureas in the management of type 2 diabetes: To be or not to be?
door: André J. Scheen
Gepubliceerd in: (2021-01-01)

Sulphonylurea therapy over six years does not delay progression to diabetes
door: Herlihy, O, et al.
Gepubliceerd in: (2000)

Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
door: Cull, C, et al.
Gepubliceerd in: (2000)

Sulphonylureas and hypoglycaemia.
door: Ferner, R, et al.
Gepubliceerd in: (1988)

UKPDS 18: Estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
door: Eeley, E, et al.
Gepubliceerd in: (1996)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
door: Matthews, DR, et al.
Gepubliceerd in: (1998)

Factors influencing utilization of different types of sulphonylureas amongst type 2 diabetes patients
door: Huri, H.Z., et al.
Gepubliceerd in: (2010)

UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. UK Prospective Diabetes Study Group.
door: Eeley, E, et al.
Gepubliceerd in: (1996)

Permanent neonatal diabetes: combining sulphonylureas with insulin may be an effective treatment
door: Misra, S, et al.
Gepubliceerd in: (2018)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
door: Turner, R, et al.
Gepubliceerd in: (1998)

New uses for old drugs: neonatal diabetes and sulphonylureas.
door: Ashcroft, F
Gepubliceerd in: (2010)

Neonatal Diabetes Caused by Activating Mutations in the Sulphonylurea Receptor
door: Peter Proks
Gepubliceerd in: (2013-06-01)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
door: Matthews, DR, et al.
Gepubliceerd in: (1998)

Post-prandial amylin concentrations are increased by sulphonylurea, but unchanged by basal insulin, in NIDDM
door: Rachman, J, et al.
Gepubliceerd in: (1996)

Extent of satisfaction with tablets and food-timing in sulphonylurea-treated diabetes.
door: Woodcock, A, et al.
Gepubliceerd in: (2007)

Should I believe all the truths?
door: Greenberg, A
Gepubliceerd in: (2018)

Pharmacogenetics in Type 2 diabetes: variation in TCF7L2 influences response to sulphonylureas
door: Pearson, E, et al.
Gepubliceerd in: (2007)

Stem cells in cancer : should we believe or not? /
door: Grande, Enrique, et al.
Gepubliceerd in: (2014)

Sulphonylureas and the rise and fall of beta-cell function
door: Matthews, DR, et al.
Gepubliceerd in: (2005)

Identification of First Case of Neonatal Diabetes in Singapore and Successful Conversion from Insulin to Sulphonylurea
door: Rashida Vasanwala MD (Paeds), MRCPCH (UK), et al.
Gepubliceerd in: (2010-06-01)

The clinical aspects ot the sulphonylurea compounds from the position of the cardioprotective approach at patient with type 2 diabetes, using glucocardiomonitoring
door: N. A. Chernikova, et al.
Gepubliceerd in: (2022-10-01)

Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients
door: Degli Esposti L, et al.
Gepubliceerd in: (2014-10-01)

Interactions between nicorandil and sulphonylureas: a structural basis.
door: Reimann, F, et al.
Gepubliceerd in: (2001)

Should metformin remain the first-line therapy for treatment of type 2 diabetes?
door: Chelsea Baker, et al.
Gepubliceerd in: (2021-01-01)

Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus
door: Fournier, Marie, et al.
Gepubliceerd in: (2014-10-01)

Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels.
door: Ammälä, C, et al.
Gepubliceerd in: (1996)

Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?
door: Geoffrey Hackett
Gepubliceerd in: (2020-07-01)

Homozygous hypomorphic HNF1A alleles are a novel cause of young-onset diabetes and result in sulphonylurea sensitive diabetes
door: Misra, S, et al.
Gepubliceerd in: (2020)

Effects of protein phosphorylation on the sulphonylurea receptor of the pancreatic beta-cell.
door: Niki, I, et al.
Gepubliceerd in: (1997)

Binding of sulphonylureas to plasma proteins – a KATP channel perspective
door: Proks, P, et al.
Gepubliceerd in: (2018)

Alternative MDR splicing is required for direct potentiation of exocytosis by sulphonylureas
door: Wendt, A, et al.
Gepubliceerd in: (2001)

Binding of sulphonylureas to plasma proteins - A KATP channel perspective.
door: Peter Proks, et al.
Gepubliceerd in: (2018-01-01)

Should an echocardiographic scan be done routinely for infants of diabetic mothers?
door: M Vural, et al.
Gepubliceerd in: (1995-10-01)

A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes.
door: Proks, P, et al.
Gepubliceerd in: (2006)

Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.
door: Hansen, A, et al.
Gepubliceerd in: (2002)

To believe or not to believe
door: Chistine Kuruç
Gepubliceerd in: (1989-12-01)

Continued Dispensing: what medications do patients believe should be available?
door: Salem Hasn Abukres, et al.
Gepubliceerd in: (2015-05-01)

Lack of association between KCNJ11 (rs5219) and ABCC8 (rs757110) polymorphisms and sulphonylurea treatment response in type 2 diabetes patients in Novosibirsk region
door: Irina Arkad'evna Bondar, et al.
Gepubliceerd in: (2015-03-01)

Involvement of the n-terminus of Kir6.2 in coupling to the sulphonylurea receptor.
door: Reimann, F, et al.
Gepubliceerd in: (1999)